CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) New Laboratory Construction Advances Rapidly

December 27, 2018 10:17:04

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a biotechnology company and drug delivery platform innovator, has submitted a Health Canada research application for a license to allow in-house research to be conducted at its Kelowna-based laboratory. A recent article further discussing the company reads, “Lexaria submitted its research application under Health Canada’s Cannabis Tracking and Licensing System for the operation of a research and development (R&D) laboratory to work with cannabinoids within the company’s new Kelowna head office, now under construction. In fact, Lexaria will commence experimental work on nicotine formulations, NSAIDs, vitamins and other bioactive compounds of interest after the completion of this laboratory facility. … The construction of the new head office and laboratory is advancing fast. Lexaria expects to occupy the new facility by the end of January 2019. The company is recruiting more staff to prepare for more wide-ranging operations. Moreover, Lexaria has taken delivery of specific equipment in a separate location where it is uniting known nano-emulsification processes with its DehydraTECH drug delivery platform for enhanced performance characteristics. This work will also transition to the Kelowna laboratory upon the facility being operational and licensed.”

To view the full article, visit

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. licenses disruptive patented delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH™ delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at

More from CannabisNewsBreaks

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published:

CannabisNewsWire (CNW)
Denver, Colorado
303.498.7722 Office